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l a c t i n e o r GH t o t h e d e c a p i t a t e . I n r a t s glycogen s t or a g e i s p r e v e n t e d i n f e t u s e s d e c a p i t a t e d on o r b e f o r e day 18 on c o n d i t i o n t h a t t h e mother i s a d r e n a l e c t o m ized; i t is r e s t o r e d s i m p l y by g i v i n g a c o r t i c o s t e r o i d . I t was s t u d i e d whether t h
e s e v a r i a t i o n s i n l i v e r g l ycogen a r e p a r a l l e l e d by v a r i a t i o n s i n plasma immunorea c t i v e i n s u l i n ( I R I ) . R a b b i t s : f e t u s e s d e c a p i t a t e d on day 24 and s t u d i e d day 29 (number i n b r a c k e t s ) : g l y c ogen=2.Ek0. 2 (10)mg/g f r e s h t i s s u e ; I R I : 7 3 ' 6 ( 1 2 ) u U / m l (human standard);controls:glycogen=26i3(11);IRI=45i4(l7). R a t s : l ) m o t h e r a d r e n a l e c t o m i z e d on d a y 14, f e t u s e s dec a p i t a t e d on day 18 and s t u d i e d on day 21:glycogen= lO.Ot6 (8)mg/g;IRI=113'16 ( 8 )~1 U / m l ( r a t s t a n d a r d ) ; 2 ) same t r e a t m e n t + lOOug c o r t i s o l a c e t a t e 24hr b e f o r e : g l y c ogen=58.4'4 (10) ;IRI=95*29(10);3)controls:glycogen= 91.3*2 ( 4 ) ; I R I = 1 3 8 * 2 1 ( 1 6 ) . The s t r i k i n g d i f f e r e n c e s i n l i v e r glycogen a r e n o t p a r a l l e l e d by s i m i l a r v a r i at i o n s i n plasma i n s u l i n . I f i n s u l i n i s r e q u i r e d f o r glycogen d e p o s i t i o n i n t h e l i v e r , it i s n o t t h e l i m it i n g f a c t o r i n d e c a p i t a t e d f e t u s e s . immunology. In 9 out of 10 cases the concentration of SM in the hepatic venal blood was found to be superior to that in the arterial blood+ The mean of the differences in SM activity (H.v.-H.A$ was + 0,29-0.10 (standard error) units/ml. This difference is significant. In these conditions, the hepatic venal blood yielded a SM activity 47% ' 16% higher than that in the humeral artery.
In the 3 cases where a second pair of samples were taken 20 or 40 minutes after the first, a similar difference was observed. However, in the 1 1 subjects tested for growth hormone, no significant difference was found between the concentration of growth hormone in the 2 types of blood. The observation of high SM levels in the efferent blood of the liver tends support to the experimental findings of McConaghey who proposed the.liver as the site of SM production. However, taking into consideration the hepatic plasma flow (measured in 3 cases < = 0.810 l/min) the importance of the differences observed must be regarded as questionable, since these would imply a very large production of SM. In this respect, the measured SM activitv has to be discussed. days of life. Growth hormone excretion in the urine was determined also in prematures. In prematures very high excretion was found in the first 3 days of life i.e. more than 1000 ng/100 ml. After 6 days excretion of 100 -1000 ng/100 rnl was found. In matures the initial excretion in the range of 500 ng/100ml decreased to less than 100 ng/lOO ml in one week. The high excretion in prematures is related to impaired renal function but also represnets increased production. It i s suggested that the increased production of growth hormone in the first days of life is related to generation of SM in the newborn.
N H U M W P I I L S M A~~I N A C T r V r r Y I N~
NrnrnTAL PERIOD ---.- .50 < x < .80:2, N.P. :3. A f t e r 4-6 weeks o f t r e a t m e n t :
low : 6, normal: 1, N.P. : 3 ( 3 had d i e d , a l l w i t h i n i t i a l S M < . 2 0 ) . A f t e r 8-10 weeks: low: 3, normal o r h i g h : 3, N.P. : 3 (one more c h i l d had d i e d ) . Nixing plasma from 3 u n t r e a t e d p a t i e n t s w i t h t h e s t a n d a r d lowered i t s a p p a r e n t potency w i t h 35, 67 and 0% r e s p . H e a t i n g plasma a f t e r a c i d i f i c a t i o n i n c r e a s e d i t s pot e n c y r e l a t i v e t o a s t a n d a r d c o n t r o l from < .12 t o .65.
C o n c l . : I n s e v e r e and c h r o n i c m a l n u t r i t i o n h e a t -l a b i l e S M -i n h i b i t i n g m a t e r i a l i s p r e s e n t i n plasma, i n i t i a l l y p e r s i s t i n g d u r i n g t r e a t m e n t . T h i s may c o n t r i b u t e t o t h e problems i n r e v e r t i n g t h e s e c h i l d r e n from a k a t ab o l i c t o a n a n a b o l i c s t a t e . The role o'f variation in end-organ cartilage response to somatomedin (SM) as a significant determinant of growth velocity has been investigated.
The response of costal cartilage of foetal and post-natal rabbits to SM has been assessed by simultaneously measuring 3 5~ and 3~-thymidine uptake in vitro.
Cartilage from rabbits of known growth rate at 2'3 and 30 days after conception (gestation 33 days), and at 1, 7, 17, 28, 39, 64, 90 and more than 200 days after birth, was studied. An excellent correlation between thymidine uptake and the growth velocity of the costal cartilage was shown. The uptake of 3 5~ was also closely related to growth velocity and the 3~/ 3 5~ ratio declined as growth rate slowed.
Serum SM of each age group was measured by the porcine cartilage technique of Van den Brande.
The post-natal serum SM increased progressively with age to an adult plateau.
This study suggests that the growth velocity of costal cartilage is determined by the combined effects of end-organ response and serum SM stimulus.
